STOCK TITAN

INCY Form 4: Director Purchase Adds 289 Shares, Holdings Now 20,608

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Edmund Harrigan, a director of Incyte Corp (INCY), acquired 289 shares of common stock on 09/30/2025 at a price of $84.81 per share. The shares were issued as restricted shares under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of a quarterly director retainer, and the filing states the restricted shares are fully vested. After this transaction, the reporting person beneficially owns 20,608 shares, which includes 2,518 shares issuable under previously reported restricted stock units that have not vested. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.

Positive

  • 289 shares acquired at $84.81 indicating director participation in company equity
  • Restricted shares are reported as fully vested, giving immediate ownership rights
  • Beneficial ownership totals 20,608 shares, providing alignment with shareholders

Negative

  • The purchase size (289 shares) is small and likely not material to company valuation
  • 2,518 shares remain issuable from previously reported RSUs and are not vested
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
HARRIGAN EDMUND

(Last) (First) (Middle)
1801 AUGUSTINE CUT-OFF

(Street)
WILMINGTON DE 19803

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
INCYTE CORP [ INCY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock(1) 09/30/2025 A 289 A $84.81 20,608(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.
2. This includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
Remarks:
/s/ Elizabeth Feeney, Attorney-In-Fact 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did INCY director Edmund Harrigan report on the Form 4?

The Form 4 reports that Edmund Harrigan acquired 289 shares of Incyte common stock on 09/30/2025 at $84.81 per share.

Were the shares acquired by the director vested or restricted?

The filing states the shares were issued as restricted shares and are reported as fully vested.

How many Incyte shares does the reporting person beneficially own after the transaction?

After the reported transaction, the reporting person beneficially owns 20,608 shares, which includes 2,518 shares issuable under previously reported restricted stock units that have not vested.

Why were restricted shares issued to the director?

Restricted shares were issued under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of a quarterly director retainer pursuant to an election by the reporting person.

Does the Form 4 indicate compliance with trading rules?

The filing notes the election was intended to comply with Rule 10b5-1.
Incyte Corp

NASDAQ:INCY

INCY Rankings

INCY Latest News

INCY Latest SEC Filings

INCY Stock Data

20.80B
192.26M
2.03%
103.47%
3.85%
Biotechnology
Services-commercial Physical & Biological Research
Link
United States
WILMINGTON